A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model
- 29 May 2014
- Vol. 32 (32) , 4068-4074
- https://doi.org/10.1016/j.vaccine.2014.05.053
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Allergy and Infectious Diseases (NIAID) (5UO1-AI078060)
This publication has 31 references indexed in Scilit:
- Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8 + T cellsProceedings of the National Academy of Sciences, 2013
- An Alphavirus Vector-Based Tetravalent Dengue Vaccine Induces a Rapid and Protective Immune Response in Macaques That Differs Qualitatively from Immunity Induced by Live Virus InfectionJournal of Virology, 2013
- Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trialThe Lancet, 2012
- Prospects for a dengue virus vaccineNature Reviews Microbiology, 2007
- Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660Vaccine, 2005
- Neonatal adaptive immunity comes of ageNature Reviews Immunology, 2004
- IL-4 Utilizes an Alternative Receptor to Drive Apoptosis of Th1 Cells and Skews Neonatal Immunity toward Th2Immunity, 2004
- Murine Neonatal CD4+ Lymph Node Cells Are Highly Deficient in the Development of Antigen-Specific Th1 Function in Adoptive Adult HostsThe Journal of Immunology, 2002
- Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virusVaccine, 2000
- Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussisThe Journal of Pediatrics, 1998